B Cell Engraftment in SCID Patients After Stem Cell Transplantation  by Martinez, Caridad et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210 S205which the patients were divided into quartiles according to
their hematologic and immunologic indices. WBC and
absolute neutrophil counts were not closely correlated with
subsequent survival. Patients in the lowest quartile of the
absolute lymphocyte and platelet count distributions,
however, experienced signiﬁcantly inferior survival beyond
one year (p¼0.012 and<0.001, respectively) when compared
with patients in the highest quartile (reference group).
Patients in the lowest quartiles of the absolute CD4+, CD19+,
CD56+, and serum IgG distributions also experienced signif-
icantly inferior survival (p¼0.019, 0.001, 0.02, and 0.023,
respectively). These results demonstrate that poor CD19+ B
cell recovery at 1 year is associatedwith inferior survival, and
suggest that interventions aimed at enhancing B cell recon-
stitution may have clinical beneﬁt.184
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Allogeneic stem cell transplant (ASCT) is a life saving
procedure for children with diverse malignant and non-
malignant conditions. The conditioning regimen renders the
patient very susceptible to infection until neutrophil (PMN)
engraftment occurs. In pediatric patients is not known if
these newly engrafted PMN's function normally, nor is it
known how long they take to become fully functional. We
hypothesize that pediatric patients, like their adult coun-
terparts, demonstrate PMN dysfunction at the time of
engraftment and beyond, which will be inﬂuenced by, the
conditioning regimen, stem cell source and level of GVHD,
and may predispose these children to serious bacterial and
fungal infections. Peripheral blood specimens were collected
from pediatric patients at Children's Hospital Colorado at 1, 2,
3, and 6 and 12months post ASCT. PMN's were isolated using
standard technique of ﬁcoll gradient, followed by hypotonic
lysis. PMN activity was assessed looking at 1) superoxide (02- )
production (luminescence); 2) azurophilic granule release
(colorimetric assay for elastase); 3) secondary granule
production (lactoferrin ELISA); 4) CD11b surface expression
(ﬂow cytometry), and; 5) phagocytosis (PhagotestTM-a ﬂow
cytometry assay).
Results: To date 22 patients have been enrolled; and over 50
samples obtained out to the 6 month post ASCT, with many
approaching 12 months post ASCT. Mean age of the partici-
pants is 10.8 years, and 65% aremale. Engraftment period has
averaged 24 days. Transplant types include eleven cord
bloods, six matched-related bone marrow donors, and three
matched-unrelated bone marrow donors. PMN function
appears to be relatively intact with no signiﬁcant differences
noted between healthy controls and sample specimens at all
time points in relation to 02- production, phagocytosis, CD11b
surface expression and lactoferrin. The lone exception is with
elastase release which is signiﬁcantly decreased at all time
points versus controls (P < .05); with a slow improvement
seen over time (Figure 1). Subgroup analysis did not show
a preferential difference in elastase release in relation to
speciﬁc stem cell source or conditioning regimen. We
conclude that similar to adults, pediatric patients have PMN
dysfunctionwhich appears to be restricted to elastase release
and continues 6 months post ASCT. A defect of this type is
somewhat similar to Chediak-Higashi and may put patientsat higher risk for serious bacterial infections, particularly
staphylococcus and streptococcus.
Figure 1.
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Stem cell transplantation (SCT) is the only curative
option for patients (pts) with Severe combined immuno-
deﬁciency (SCID). Adequate T cell function is usually ach-
ieved in these pts after SCT. Unfortunately, however,
adequate B cell function often fails, and little is known
about how disease type, conditioning or stem cell graft
inﬂuence this process. We report B cell function reconsti-
tution following SCT (1998-2012) in 35 SCID pts: IL2RG
(n¼13), JAK3 (n¼2), RAG1, 2 (n¼2), IL7RA (n¼5), CD3D
(n¼4), Zap70 (n¼2), MHCII def (n¼1), ADA (n¼2), and not
differentiated (n¼4). Fourteen pts received a haploidentical
donor graft, 8 pts a matched related donor (MRD) graft, 7
pts a matched/mismatched unrelated donor (MUD/MMUD)
graft, and 7 pts a mismatched unrelated cord blood
(MMUCB) graft. One pt received a MMUCB after a hap-
loidentical graft failure. 23 pts underwent ablative condi-
tioning with busulfan, cyclophosphamide, and ﬂudarabine
or cytarabine, 7 pts a reduced intensity conditioning using
ﬂudarabine and anti-CD52 and/or anti-CD45. Five pts were
not conditioned. Anti-CD52 was used in 22 pts. MMUCB
recipients receive no serotherapy. Overall survival of the
entire cohort was 87% with a median follow up of 6 years
(range, 0.5 -13 years); MRD and MMUCB graft recipients
had a 100% survival. To determine functional B cell
engraftment we measured IgA and total IgG. Engraftment
was considered successful when IgA was normal and levels
of IgG were above 500 mg/dL without supplemental IVIG.
Adequate B cell function of the whole group occurred at
a median time of 4 years (range, 2-13 years) in the hap-
loidentical and MRD recipients, at 3 years (range, 2-6 years)
in the MUD/MMUD recipients and at just 6 months (range,
4-11 months) in the MMUCB recipients. Five of 28 evalu-
able patients (3/14 haplo and 2/8 MUD) failed to achieve
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infusions. All 5 patients with absence of B cell function had
less than 25% B cell donor engraftment and 3 of them had
received ablative conditioning. Less than 25% donor B cell
engraftment correlated with abscense of function (P ¼
.006). 4/5 patients with absent B cell function have IL2RG
genetic defect (OR¼5.12, P ¼ .038). All the recipients of
MMUCB achieved faster and more reliable B cell function
compared to other donor sources (P ¼ .003). Hence absence
of adequate B cell function is most closely associated with
pts who have IL2RG defect irrespective of conditioning. In
addition, donor source inﬂuence the speed and probably
the ultimate success of B cell engraftment (MMUCB>haplo
donors).186
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TKIs are known to affect T and NK cells. We therefore
assessed immunological reconstitution and function in 24
pts with advanced CML and Ph+ ALL who received Nicotinib
as maintenance therapy post alloSCT (study CAM-
N107AIL03T). At 6 months after alloSCT, 11 of 15 pts with
advanced CML had attained CCyR, 11 of 15 pts with advanced
CML had attained a MMR or better, and 5 of 7 pts with Ph+
ALL attained a CR. The median OS was 16 months, with
predicted 1- and 2- year rates of 55% (95% CI, 32% e 72%) and
50% (95% CI, 28%e 68%), respectively. The median PFS was 11
months, with predicted 1- and 2- year rates of 50% (95% CI,
28% e 68%) and 38% (95% CI, 17% e 59%), respectively.
Immunological testing was performed pre- and post Niloti-
nib maintenance therapy in 12 pts in this study. The relative
percentage of T- lymphocyte subsets (assessed by FACS) and
total lymphocytes number were stable during Nilotinib
maintenance therapy, while a 7.82.5 fold increase in B cells
was noted. T cell mitogenic response with aCD3 and PHA
(stimulation index ratio) was sustained (2.51.0, vs. 2.81.05
and 3.31.3 vs. 5.32.9 stimulation. Mean thymic output
determined by TREC quantiﬁcation pre-, during and post
Nilotinib administration was 81.8108, 81.290.3 andTable
3 Months after dUCBT
dmPGE2-
dominant
Untreated/
Untreated-
dominant
P value -
T test
WBC 5900.0 4850.0 0.377
CD3+ count 10.6 50.0 0.097
% CD3+ of lymphocytes 2.55% 11.00% 0.066
Richness Alpha Diversity 585 3905
Clonality 1-Normalized
Entropy
0.1381 0.2454 0.090
Total Repertoire Overlap Index
Persistence of Top 10 Clones142.8197.4 copies per 0.5ug DNA indicating continuous
thymopoiesis. Similarly, no signiﬁcant change of the TCR
repertoire was observed during Nilotinib treatment. Normal
expression of the TCR repertoire was detected in 15.15.5
and 15.35.6 of the examined TCRs. NK cytotoxic activity
against K562 expressed as fold of change from baseline, also
remained stable during Nilotinib treatment (2.81.1 and
2.30.8, respectively). In summary, Nilotinib maintenance
therapy post alloSCT in pts with advanced CML and Ph+ALL
did not interfere or jeopardized immune reconstitution and
function.187
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In double umbilical cord blood (UCB) transplantation
(dUCBT), ex vivo modulation of a single UCB unit with 16,
16 dimethyl prostaglandin E2 (dmPGE2) accelerates
neutrophil engraftment and leads to preferential hemato-
poietic dominance with complete T cell chimerism as early
as 13 days from dUCBT. We sought to determine whether
dmPGE2 affected the recovery of T cell diversity after
dUCBT.
Methods: dUCBT recipients received ﬂudarabine, melphalan,
and ATG conditioning with Tacrolimus and Sirolimus GvHD
prophylaxis. TCRb CDR3 regions were ampliﬁed and
sequenced using the ImmunoSeq assay (Adaptive Biotech-
nologies) from a median of 171 ng of T cell gDNA (range 0.8 -
400.0 ng) at 3 and 12 months from dUCBT. We analyzed 5
paired samples with dmPGE2-dominance (PD); 3 paired and
7 single 12 month untreated (U) samples; and 5 paired and 1
single 12 month dmPGE2 treated sample with untreated-
dominance (UD). The U+UD groups were combined as one
control cohort.
Results: PD CD3+ cells were lower at 3 months versus the
U+UD group (P ¼ .057, Table) but this trend diminished by 12
months (P ¼ .11). Lower CD3+ counts were reﬂected in lower
total TCR alpha diversity in PD samples at both time points (3
month median 585 vs. 3905 unique TCR sequences, P ¼ .079;12 Months after dUCBT
P value -
U test
dmPGE2-
dominant
Untreated/
Untreated-
dominant
P value -
T test
P value -
U test
1 4300.0 6500.0 0.049 0.035
0.26 159.4 444.2 0.016 0.014
0.057 12.30% 31.85% 0.161 0.11
0.079 2729 12062.5 0.22
0.19 0.1105 0.2326 0.945 0.54
0.0873 0.3884 0.027 0.057
2 10 0.040
